JP2017506257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506257A5 JP2017506257A5 JP2016558543A JP2016558543A JP2017506257A5 JP 2017506257 A5 JP2017506257 A5 JP 2017506257A5 JP 2016558543 A JP2016558543 A JP 2016558543A JP 2016558543 A JP2016558543 A JP 2016558543A JP 2017506257 A5 JP2017506257 A5 JP 2017506257A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- agx51
- substituted
- dioxol
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 230000002001 anti-metastasis Effects 0.000 claims 10
- -1 2-bromovinylamino, hydroxymethyl Chemical group 0.000 claims 9
- 230000004069 differentiation Effects 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004066 vascular targeting agent Substances 0.000 claims 5
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000002459 sustained effect Effects 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- GCIQSQDZEOOMQQ-UHFFFAOYSA-N 2-[1-(1,3-benzodioxol-5-yl)-3-(benzylamino)propyl]phenol Chemical compound OC1=C(C=CC=C1)C(CCNCC1=CC=CC=C1)C1=CC2=C(OCO2)C=C1 GCIQSQDZEOOMQQ-UHFFFAOYSA-N 0.000 claims 1
- NEDLYQXZCPTKOD-UHFFFAOYSA-N 2-methyl-3-phenylpropanamide Chemical class NC(=O)C(C)CC1=CC=CC=C1 NEDLYQXZCPTKOD-UHFFFAOYSA-N 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- GYJCXQBSVOOFKS-UHFFFAOYSA-N N-[3-(1,3-benzodioxol-5-yl)-3-(2-hydroxyphenyl)propyl]-N-benzylpropanamide Chemical compound CCC(=O)N(CCC(C1=CC2=C(OCO2)C=C1)C1=C(O)C=CC=C1)CC1=CC=CC=C1 GYJCXQBSVOOFKS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 125000002577 pseudohalo group Chemical group 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000005000 thioaryl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916116P | 2013-12-13 | 2013-12-13 | |
| US61/916,116 | 2013-12-13 | ||
| US201461965776P | 2014-02-06 | 2014-02-06 | |
| US61/965,776 | 2014-02-06 | ||
| PCT/US2014/070221 WO2015089495A2 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162598A Division JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506257A JP2017506257A (ja) | 2017-03-02 |
| JP2017506257A5 true JP2017506257A5 (enrdf_load_stackoverflow) | 2018-02-01 |
Family
ID=53371974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558543A Pending JP2017506257A (ja) | 2013-12-13 | 2014-12-14 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
| JP2019162598A Withdrawn JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162598A Withdrawn JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3079680A4 (enrdf_load_stackoverflow) |
| JP (2) | JP2017506257A (enrdf_load_stackoverflow) |
| CN (1) | CN107847470A (enrdf_load_stackoverflow) |
| AU (1) | AU2014361814A1 (enrdf_load_stackoverflow) |
| MX (1) | MX2016007748A (enrdf_load_stackoverflow) |
| WO (1) | WO2015089495A2 (enrdf_load_stackoverflow) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000548B2 (en) * | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| AU2017219415B2 (en) | 2016-02-18 | 2023-08-10 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
| EP3760614B8 (en) * | 2019-07-02 | 2022-04-27 | Universität Heidelberg | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
| JP2022550589A (ja) * | 2019-10-01 | 2022-12-02 | メモリアル スローン ケタリング キャンサー センター | Ｉｄタンパク質の小分子阻害剤 |
| CN113627763B (zh) * | 2021-07-30 | 2023-12-01 | 厦门大学 | 一种风险量化评估模型建立方法 |
| CN114480490A (zh) * | 2021-12-31 | 2022-05-13 | 四川省医学科学院·四川省人民医院 | 一种构建视网膜新生血管性疾病动物模型的方法 |
| CN115487358B (zh) * | 2022-08-05 | 2023-05-30 | 核工业四一六医院 | 一种用于软骨组织修复的凝胶复合支架及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| US20130171158A1 (en) * | 2010-06-30 | 2013-07-04 | Garvan Institute Of Medical Research | Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| WO2013025939A2 (en) * | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
-
2014
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/zh active Pending
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/ja active Pending
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/es unknown
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/en not_active Withdrawn
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en active Application Filing
-
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506257A5 (enrdf_load_stackoverflow) | ||
| US10246406B2 (en) | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof | |
| AU2016256471B2 (en) | Methods of treating cancer | |
| CN103998035B (zh) | 包含格列酮和nrf2激活剂的药物组合物 | |
| TWI791507B (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
| JP7262118B2 (ja) | 医薬組成物およびその使用 | |
| ES2896735T3 (es) | Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida | |
| JP2016516074A5 (enrdf_load_stackoverflow) | ||
| BRPI1013259B1 (pt) | Moduladores lxr | |
| JP2008528489A (ja) | Ｑｔ間隔調節方法 | |
| JP2014515407A5 (enrdf_load_stackoverflow) | ||
| CN114025766A (zh) | 用于抑制gapdh的噁噻嗪化合物 | |
| AU2019274870B2 (en) | Method of treating pain or interstitial cystitis using indole compound | |
| US20220395577A1 (en) | Methods and materials for modulating nrf2 pathway | |
| WO2021066136A1 (ja) | 筋ジストロフィー治療薬 | |
| US11389434B2 (en) | Methods and pharmaceutical compositions for the treatment of mast cell diseases | |
| JP2014505074A5 (enrdf_load_stackoverflow) | ||
| JPH09500375A (ja) | パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用 | |
| WO2019211783A1 (en) | Indoleamine 2,3-dioxygenase signalling modulator and therapeutic use thereof | |
| WO2024095118A1 (en) | Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis | |
| HK40067738A (en) | Oxathiazin compounds for inhibiting gapdh | |
| HK40049577B (en) | Indole compound for treating interstitial cystitis | |
| HK40049577A (en) | Indole compound for treating interstitial cystitis | |
| JP2020522565A (ja) | プロスタグランジンｅ２の生成を阻害する多置換されたピリミジン、その製造方法およびその使用 |